Show simple item record

dc.contributor.authorEl-Salhy, Magdy
dc.contributor.authorBråthen Kristoffersen, Anja
dc.contributor.authorValeur, Jørgen
dc.contributor.authorCasén, Christina
dc.contributor.authorHatlebakk, Jan Gunnar
dc.contributor.authorGilja, Odd Helge
dc.contributor.authorHausken, Trygve
dc.date.accessioned2021-09-09T06:14:07Z
dc.date.available2021-09-09T06:14:07Z
dc.date.created2021-06-19T13:51:39Z
dc.date.issued2021
dc.identifier.issn1350-1925
dc.identifier.urihttps://hdl.handle.net/11250/2774781
dc.description.abstractBackground We recently found fecal microbiota transplantation (FMT) in irritable bowel syndrome (IBS) patients to be an effective and safe treatment after 3 months. The present follow-up study investigated the efficacy and safety of FMT at 1 year after treatment. Methods This study included 77 of the 91 IBS patients who had responded to FMT in our previous study. Patients provided a fecal sample and completed five questionnaires to assess their symptoms and quality of life at 1 year after FMT. The dysbiosis index (DI) and fecal bacterial profile were analyzed using a 16S rRNA gene-based DNA probe hybridization. The levels of fecal short-chain fatty acids (SCFAs) were determined by gas chromatography. Results There was a persistent response to FMT at 1 year after treatment in 32 (86.5%) and 35 (87.5%) patients who received 30-g and 60-g FMT, respectively. In the 30-g FMT group, 12 (32.4%) and 8 (21.6%) patients showed complete remission at 1 year and 3 months, respectively; the corresponding numbers in the 60-g FMT group were 18 (45%) and 11 (27.5%), respectively. Abdominal symptoms and the quality of life were improved at 1 year compared with after 3 months. These findings were accompanied by comprehensive changes in the fecal bacterial profile and SCFAs. Conclusions Most of the IBS patients maintained a response at 1 year after FMT. Moreover, the improvements in symptoms and quality of life increased over time. Changes in DI, fecal bacterial profile and SCFAs were more comprehensive at 1 year than after 3 months. www.clinicaltrials.gov (NCT03822299).en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleLong-term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndromeen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2021 The Authorsen_US
dc.source.articlenumbere14200en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.doi10.1111/nmo.14200
dc.identifier.cristin1916927
dc.source.journalNeurogastroenterology and Motilityen_US
dc.identifier.citationNeurogastroenterology and Motility. 2021, e14200.en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal